All News

PsA Potpourri Dr. Arthur Kavanaugh reviewed highlights on adult and pediatric sessions on uveitis, as well as interesting abstracts, at #ACR24 https://t.co/jsCMKHBFMk https://t.co/roZOZT3Mqd

Links:

Dr. John Cush RheumNow ( View Tweet)
light-bulbs-1125016_640.jpg

A new score to quantify GCA inflammation?

d Eric Dein, MD

The treatment paradigm for Giant Cell Arteritis (GCA) has been a binary approach to the presence or absence of vasculitis. When GCA is present, we institute high doses of glucocorticoids for treatment of the inflammatory process. This approach is not well individualized to the patient as we do not account for the degree of inflammation that may or may not be present in the disease. Improved markers to stratify the extent of inflammation can help to tailor a more personalized approach to treatment.

Read Article
Biggest absence award at #ACR24 @ACRheum @RheumNow 🥇 Absence of discussion on 👇 #Oral #Surveillance Except for maybe Monitoring for mouth ulcers and cancers issues are not resolved but we are comfortable with ambiguity!

Janet Pope Janetbirdope ( View Tweet)

Risk stratification of GCA pts: who might lose vision? Cranial MRI with vessel wall enhancement used to calculate additive score... # of vessels affected Higher scores a/w ocular GCA > non-ocular GCA > no GCA and decreased w/ tx @RheumNow #ACRbest #ACR24 https://t.co/knDVrl84Qs

Links:

Brian Jaros, MD Dr_Brian_MD ( View Tweet)
Yang et al. Cranial vessel wall MRI in GCA. Quantitated with PEG score. PEG score ocular GCA>non-ocular GCA>non-GCA. Decreases with treatment. @RheumNow #ACR24 Abstr#2650 https://t.co/e26urOpb7V https://t.co/eekQbzmKYm

Links:

Richard Conway RichardPAConway ( View Tweet)
Yang et al. Cranial vessel wall MRI in GCA. Quantitated with PEG score. PEG score ocular GCA>non-ocular GCA>non-GCA. Decreases with treatment. @RheumNow #ACR24 Abstr#2650 https://t.co/e26urOpb7V https://t.co/eekQbzmKYm

Links:

Richard Conway RichardPAConway ( View Tweet)
A#2650 MRI can show extent of vessel wall inflamm to guide severity of GCA Brain & orbital MRI performed Assessed 7 arteries bilaterally -> CAMRIS-GCA MRI score (0-10) 33 GCA (17 ocular), 41 not GCA CAMRIS-GCA ass w/ ocular GCA, higher severity. Improved w Rx @RheumNow #ACR24 https://t.co/19XCuZJXqF

Links:

Eric Dein ericdeinmd ( View Tweet)
Low uveitis rates in patients with axial spondyloarthritis and psoriatic arthritis treated with bimekizumab (BKZ) over the long term. Key findings: - AxSpA: 3.7% incidence (1.3/100 PY) with BKZ. - PsA: Only 0.2% incidence (0.1/100 PY). - All events were mild/moderate, with no… https://t.co/jkUwHJk3FJ https://t.co/gTcCzeC88e

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Low uveitis rates in patients with axial spondyloarthritis and psoriatic arthritis treated with bimekizumab (BKZ) over the long term. Key findings: - AxSpA: 3.7% incidence (1.3/100 PY) with BKZ. - PsA: Only 0.2% incidence (0.1/100 PY). - All events were mild/moderate, with no… https://t.co/jkUwHJk3FJ https://t.co/gTcCzeC88e

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Single cell TCR sequence study explores the limitations of TRBV9-depleting therapies in axial spondyloarthritis. Key findings: - Identified a clonally expanded TRBV5-5+ TCR in HLA-B27+ acute anterior uveitis. - Alternative TRBVs may retain pathogenicity and evade anti-TRBV9… https://t.co/Aj8oslsTNX

Links:

Antoni Chan MD (Prof) synovialjoints ( View Tweet)

Which subsets of GCA pt might benefit most from upadacitinib? Sub-analysis from SELECT-GCA presented today: 💥Both relapsing and refractory disease 💥Pt w hx of PMR 💥Non-smokers 💥No hx ischemic eye dz In general, most subgroups still favor UPA @RheumNow #ACR24 Abst 1695 https://t.co/pX5hcX4TmR

Links:

Brian Jaros, MD Dr_Brian_MD ( View Tweet)
#Blinded by results? 😊 #Ocular #involvement in #GPA 👇 Helped by #rituximab 👁️ #GPA Difficult Proptosis Pseudotumour Conjunctivitis Scleritis Vasculitis Ocular muscles - diplopia Small case series ‘author defined’ remission in 80% 👍 #RTX #abst0726 @rheumnow #ACR24 https://t.co/GHptelOTyv

Links:

Janet Pope Janetbirdope ( View Tweet)
back, LBP, spine, AS

Difficult to Manage Axial Spondyloarthritis

d Adela Castro, MD

Studies show that patients with difficult-to-manage axSpA have a higher disease activity; however, the lack of a consensus definition led researchers and clinicians to utilize their own proposed definition, resulting in variability of the characteristics of non-responders.

Read Article
Systematic review suggests (although not provn) that audiovestibular dysfunction may be from APS. Anti-phospholipid & HSP-70 Abs found 25-33% w/idiopathic sudden sensorineural hearing loss,. ACL Abs seen in up to 27% w/ sensorineural hearing loss https://t.co/GTcLoM0SCZ https://t.co/afFntYnPPG

Links:

Dr. John Cush RheumNow ( View Tweet)
Overview of Uveitis management of adult & pediatric rheumatology. - Uveitis accounts for 10% of visual impairment globally - TNF inhib are effective; w/ IL-6 inhib as 2nd line options https://t.co/CmGuA7W4Ag https://t.co/p5aEQlV7p6

Links:

Dr. John Cush RheumNow ( View Tweet)
uveitis.3.jpg

Risk of Uveitis with Spondyloarthritis

d Jack Cush, MD

A retrospective registry study shows that uveitis may be seen in 10% with the diagnosis of axial spondyloarthritis (axSpA) but becomes more common (47%) over the next 30 years of disease. The good news is that biologic therapy can significantly lower the risk of uveitis in (SpA).

Read Article
🌟 ACUTE OPTIC NEURITIS - Differentials https://t.co/eE1Kbnmqc1

Links:

Dr. Akhil 🇮🇳 DrAkhilX ( View Tweet)
RheumNow Podcast square

Linger on the Fingers (9.6.2024)

d Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. This week with a focus on fingers and better prescriptive follow through.

Read Article
Immunomodulatory Prevention of Uveitis Relapse in Behçet's The results of a randomised, open-label, head-to-head trial shows that adalimumab was superior to ciclosporin in preventing uveitis relapses in patients with severe Behçet's disease. https://t.co/12fpuIZFmA https://t.co/iDJJq29JMA

Links:

Dr. John Cush RheumNow ( View Tweet)
Pooled data from BE MOBILE 1 & 2 RCTs shows Bimekizumab (dual-IL-17A/F inhib) may protect against uveitis in axSpA pts. N=349 pts - 0.6% BKZ vs 4.6% placebo developed uveitis (1.8 vs 15.4/100 PYs); even in pts w/ Hx of uveitis (6.2 vs 70/100 PYs; p=0.004) https://t.co/f8Uk0rEg86 https://t.co/mY1ikcGCNP

Links:

Dr. John Cush RheumNow ( View Tweet)

Do you get our email newsletter?

Looking for the latest rheumatology news & trends? Sign up for the RheumNow weekday newsletter:

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.

Copyright {{ 'now'|date('Y') }} All Rights Reserved.